Telos Capital Management Inc. acquired a new stake in VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 5,555 shares of the company’s stock, valued at approximately $608,000. Telos Capital Management Inc. owned 0.06% of VanEck Pharmaceutical ETF at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Commonwealth Equity Services LLC purchased a new position in VanEck Pharmaceutical ETF during the 3rd quarter valued at about $1,171,000. ARQ Wealth Advisors LLC lifted its holdings in VanEck Pharmaceutical ETF by 7.2% in the 3rd quarter. ARQ Wealth Advisors LLC now owns 11,443 shares of the company’s stock worth $1,253,000 after buying an additional 769 shares during the period. North Star Investment Management Corp. purchased a new stake in VanEck Pharmaceutical ETF in the 3rd quarter worth approximately $64,000. Latitude Advisors LLC purchased a new stake in VanEck Pharmaceutical ETF in the 3rd quarter worth approximately $55,000. Finally, Oppenheimer & Co. Inc. bought a new stake in shares of VanEck Pharmaceutical ETF in the 3rd quarter worth approximately $711,000.
VanEck Pharmaceutical ETF Stock Performance
Shares of PPH stock opened at $119.01 on Friday. VanEck Pharmaceutical ETF has a fifty-two week low of $93.11 and a fifty-two week high of $123.53. The firm has a market cap of $1.14 billion, a P/E ratio of 20.21 and a beta of 0.43. The business’s 50 day moving average price is $112.83 and its 200-day moving average price is $108.23.
VanEck Pharmaceutical ETF Cuts Dividend
The firm also recently declared a quarterly dividend, which was paid on Tuesday, October 6th. Investors of record on Thursday, October 1st were paid a $0.36 dividend. The ex-dividend date of this dividend was Thursday, October 1st. This is a negative change from VanEck Pharmaceutical ETF’s previous quarterly dividend of $0.6248. This represents a $1.44 dividend on an annualized basis and a yield of 1.2%.
About VanEck Pharmaceutical ETF
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.
Recommended Stories
- Five stocks we like better than VanEck Pharmaceutical ETF
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Want to see what other hedge funds are holding PPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report).
Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.
